ONC

BeOne Medicines Ltd. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-02-26

Figures on this page computed 2026-11-08 13:21 UTC

Last close

377.78USD

Market data, 2026-11-04

ONC: weekly closes from 319.97 on 2025-11-07 to 377.78 on 2026-11-04, a move of +18.1%. Prices in USD.

Weekly closes, 2025-11-07 to 2026-11-04

Over that span: +18.1%

Except where said otherwise: 10-K for 2025, filed 2026-02-26

2034.8xP/E
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001628280-26-011946
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-26
The filing itself
33.6%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001628280-26-011946
Reported in
USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-08-05
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-08-05
The filing itself
5.4%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001628280-26-011946
Reported in
USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
The filing itself
17.6%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001628280-26-011946
Reported in
USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
The filing itself
0.25Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001628280-26-011946
Reported in
USD
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-08-05
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Price is the furthest below its sector's middle: 0.01 against 0.36 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

3.47x

-0.35x

-1.21x

1.73x

1.89x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-04

Each against its own average

5 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-02-26

Sales3.47x
Its own average over 10 years, 1.54B.
Profit-0.35x
Its own average over 10 years, -816.1M.
Free cash flow-1.21x
Its own average over 10 years, -780.0M.
Debt1.73x
Its own average over 10 years, 638.4M.
Price1.89x
Its own average over 11 years, 200. Market data, 2026-11-04

Sales is furthest from its own average, at 3.47 times.

The filed years, as a table

Each line is 100 at 2016-12-31, the first year we hold.

Filed year	Sales	Shares in issue
2016-12-31	100.0	n/a
2017-12-31	22,279.2	n/a
2018-12-31	18,525.2	n/a
2019-12-31	40,019.8	100.0
2020-12-31	28,866.7	139.0
2021-12-31	109,933.0	154.5
2022-12-31	132,329.1	171.7
2023-12-31	229,792.4	173.8
2024-12-31	356,097.3	175.3
2025-12-31	499,348.9	188.9

How sales was got

Source: filed
Statement: income
Fiscal year: 2025
Accession: 0001628280-26-011946
Reported in: USD

The filing itself

How shares in issue was got

Source: filed
Statement: income
Fiscal year: 2025
Accession: 0001628280-26-011946
Reported in: USD

The filing itself

Figures behind the shape

Growth

76.8%

faster is higher, placed against 4,950 companies as of 2026-11-07

Five-year revenue growth rate76.8%
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
Five-year EPS growth raten/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
One-year change in net income144.5%
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Returns on capital

33.6%

higher is higher, placed against 5,089 companies as of 2026-11-07

Return on invested capital33.6%
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001628280-26-011946
Reported in
USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-08-05
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-08-05
The filing itself
Return on equity6.6%
Net Income / Shareholders' Equity x 100
Source
computed
Fiscal year
2025
Accession
0001628280-26-011946
Reported in
USD
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-08-05
The filing itself
Return on assets3.5%
Net Income / Total Assets x 100
Source
computed
Fiscal year
2025
Accession
0001628280-26-011946
Reported in
USD
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-08-05
The filing itself

Margins

87.5%

wider is higher, placed against 3,412 companies as of 2026-11-07

Gross margin87.5%
Gross Profit / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001628280-26-011946
Reported in
USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
The filing itself
Operating margin8.4%
Operating Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001628280-26-011946
Reported in
USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
The filing itself
Net margin5.4%
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001628280-26-011946
Reported in
USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
The filing itself
Free cash flow margin17.6%
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001628280-26-011946
Reported in
USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
The filing itself

Price

2034.8x

cheaper is higher, placed against 4,362 companies as of 2026-11-07

Price to earnings2034.8x
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001628280-26-011946
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-26
The filing itself
Price to book137.6x10-Q for 2025, filed 2026-08-05
Price / Book Value per Share, where BVPS = Shareholders' Equity / Diluted Shares
Source
computed
Fiscal year
2025
Accession
0001628280-26-052878
Reported in
USD
- computed
- 10-Q for 2025, filed 2026-08-05
- computed
- 10-K for 2025, filed 2026-02-26
The filing itself
EV to EBITDA1013.5x
Enterprise Value / EBITDA, where EV = Market Cap + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001628280-26-011946
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-08-05
- 10-K for 2025, filed 2026-02-26
The filing itself
Price to sales ratio112.3x
Market Cap / Revenue, where Market Cap = Price x Diluted Shares
Source
computed
Fiscal year
2025
Accession
0001628280-26-011946
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
The filing itself

Safety

0.25

safer is higher, placed against 3,227 companies as of 2026-11-07

Debt to equity0.25
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001628280-26-011946
Reported in
USD
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-08-05
The filing itself
Current ratio3.4110-Q for 2025, filed 2026-08-05
Current Assets / Current Liabilities
Source
computed
Fiscal year
2025
Accession
0001628280-26-052878
Reported in
USD
- 10-Q for 2025, filed 2026-08-05
- 10-Q for 2025, filed 2026-08-05
The filing itself
Interest coverage7.7x
Operating Income / Interest Expense
Source
computed
Fiscal year
2025
Accession
0001628280-26-011946
Reported in
USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
The filing itself
Altman Z-Score94.15
1.2 x A + 1.4 x B + 3.3 x C + 0.6 x D + 1.0 x E (A=WC/TA, B=RE/TA, C=EBIT/TA, D=MktCap/TL, E=Rev/TA)
Source
computed
Taken on
2026-11-07
Reported in
USD
- Computed from the 10-K for 2025, filed 2026-02-26
- Computed from the 10-K for 2025, filed 2026-02-26
- Computed from the 10-K for 2025, filed 2026-02-26
- Computed from the 10-K for 2025, filed 2026-02-26
- Computed from the 10-K for 2025, filed 2026-02-26

What it pays out

n/a

We do not hold this figure for this company, so there is nothing to place.

more, and better covered, is higher, with no cohort held

Dividend yieldn/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
Payout ration/a
We do not hold this figure for this company, so there is nothing to place.
Common Dividends Paid / Net Income x 100, both from the latest filed fiscal year
Source
computed
Fiscal year
2025
Accession
0001628280-26-011946
Reported in
USD
- 10-K for 2025, filed 2026-02-26
- Computed from the 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
The filing itself
Dividend cover ration/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Share a finding

A link to the finding, not to you: it carries nothing about your account.